Cyclin-dependent protein kinase (CDK) has been clinically applied in the treatment of breast cancer, which promotes the phosphorylation of tumor suppressor gene Rb and enables cells to enter the S phase from the G1 phase. CDK4/6 inhibitors can inhibit the activity of breast cancer, head and neck cancer, non-small cell lung cancer, and other malignant tumors. Glioblastoma has the characteristics of high recurrence rate, short survival time, and poor prognosis, which makes it difficult to treat. CDK4/6 is theoretically the target of glioblastoma treatment. CDK4/6 inhibitors act on one of the three classical pathways-the cyclin D-CDK4/6-INK4-Rb pathway, and also can inhibit glioblastoma. As promising drugs for the treatment of glioblastoma, CDK4/6 inhibitors have proved their inhibitory effects on glioblastoma, according to a large amount of evidence from animal experiments and tumor cell line and other studies. The development direction of CDK4/6 inhibitors is to search for predictive markers and to explore combined treatment to try to solve the key problems of drug resistance and recurrence in the treatment of glioblastoma, and to provide new directions and ideas for the treatment of glioblastoma.